Roche: Phase III OCREVUS high dose in MS misses primary endpoint

 

• MUSETTE trial was designed to determine whether a higher dose of the currently approved OCREVUS IV 600 mg would provide additional benefit to people living with relapsing multiple sclerosis
• The trial did not meet its primary endpoint; results support OCREVUS IV 600 mg as the optimal dose to slow disability progression
• High dose was well tolerated with an overall comparable safety profile to OCREVUS IV 600 mg and no new safety signals observed
• These data further support the efficacy and safety profile of OCREVUS IV 600 mg dose for RMS
• OCREVUS set a new standard of care in multiple sclerosis and is the most prescribed disease modifying therapy in the United States with more than 400,000 people treated globally
• https://www.roche.com/investors/updates/inv-update-2025-04-02b